Group 1 - Bionano Genomics, Inc. has launched a public offering of 5 million shares at a price of $2.00 per share, aiming to generate $10 million in gross proceeds, with potential additional funds of $20 million if warrants are fully exercised [1][2] - The funds from the offering are intended to support general corporate needs and will provide a solid foundation for the company's expansion into clinical and anatomic pathology [2][3] - The company is focusing on enhancing utilization among routine users, strengthening its installed base, accelerating adoption of its VIA software, and developing reimbursement support for its optical genome mapping (OGM) technology [3][4] Group 2 - Bionano Genomics, Inc. is based in San Diego, California, and specializes in genome analysis solutions, aiming to transform the understanding of the genome since its founding in 2003 [4]

Market Overview - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 100 points on Thursday [1] - The Dow decreased by 0.04% to 46,000.59, while the NASDAQ rose by 0.49% to 22,370.12 and the S&P 500 increased by 0.29% to 6,619.34 [1] Sector Performance - Information technology shares increased by 0.8% on Thursday [1] - Materials stocks fell by 0.7% [2] Economic Indicators - U.S. initial jobless claims declined by 33,000 to 231,000 in the second week of September, better than market estimates of 240,000 [3][9] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest level since January, compared to -0.3 in August [11] Commodity Prices - Oil prices increased by 0.5% to $64.37, while gold decreased by 0.4% to $3,701.70 [6] - Silver fell by 0.1% to $42.110 and copper dropped by 0.5% to $4.6135 [6] International Markets - European shares were higher, with the eurozone's STOXX 600 rising by 0.8% [7] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% and Hong Kong's Hang Seng falling by 1.35% [8] Company News - 89bio, Inc. shares surged 85% to $14.97 after announcing an acquisition agreement with Roche [10] - Aeries Technology, Inc. shares also rose 85% to $1.0500 following a partnership announcement with an annual contract value of up to $8 million [10] - Aptevo Therapeutics Inc. shares increased by 57% to $2.2201 after breakthrough clinical results [10] - Replimune Group, Inc. shares dropped by 40% to $3.4288 as the company evaluates FDA feedback [10] - BioCardia, Inc. shares fell by 34% to $1.02 after announcing a public offering and trial results [10] - Office Properties Income Trust shares decreased by 28% to $0.4066 [10]

Core Viewpoint - Bionano Genomics, Inc. has successfully closed a public offering, raising approximately $10 million, with potential additional proceeds of around $20 million from Series Warrants if fully exercised [1][3]. Group 1: Offering Details - The public offering consisted of 5,000,000 shares of common stock and Series E and Series F warrants, all priced at $2.00 per share [1]. - The Series E warrants will expire five years after issuance, while the Series F warrants will expire eighteen months after issuance [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering were approximately $10 million before deducting fees and expenses [3]. - If the Series Warrants are fully exercised, the potential additional gross proceeds could reach approximately $20 million [3]. - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions and offers diagnostic services and software [6]. - Bionano's mission is to transform genome analysis through innovative technologies, including proprietary isotachophoresis (ITP) [6].

Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - NASDAQ fell 0.03% to 22,341.05, and S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - Adjusted earnings for Dave & Buster's were 40 cents per share, below estimates of 92 cents per share [2] Commodities - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell 0.1% to $4.7120 [5] European Markets - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, and London's FTSE 100 fell 0.74% [6] Asian Markets - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - The NASDAQ fell 0.03% to 22,341.05, and the S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - The company reported adjusted earnings of 40 cents per share, falling short of estimates of 92 cents per share [2] Commodity Market - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell by 0.1% to $4.7120 [5] European Market - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, London's FTSE 100 fell 0.74%, Germany's DAX 40 dipped 1.29%, and France's CAC 40 fell 0.72% [6] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

Core Viewpoint - Bionano Genomics, Inc. has announced a public offering of 5,000,000 shares of common stock and associated Series E and Series F warrants, aiming to raise approximately $10 million before expenses, with potential additional proceeds of about $20 million if the warrants are fully exercised [1][3]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with Series E warrants expiring in five years and Series F warrants expiring in eighteen months [1]. - The offering is expected to close on or about September 17, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $10 million before deducting fees and expenses [3]. - If fully exercised, the Series Warrants could provide an additional gross proceeds of approximately $20 million [3]. - The net proceeds will be used for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions, diagnostic services, and software, with a mission to transform genome analysis [6]. - Bionano also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology [6].

Core Insights - Bionano Genomics has published a book series focusing on chromoanagenesis, emphasizing the advantages of optical genome mapping (OGM) in this area of research [1][4] - Chromoanagenesis is linked to complex karyotypes and poor prognosis in cancers, making its detection crucial for understanding disease biology [2][4] - OGM offers high-resolution genome-wide views of structural variants, facilitating the identification of genomic variations associated with chromoanagenesis [2][4] Company Overview - Bionano Genomics specializes in genome analysis solutions, aiming to transform genomic insights through OGM technology and related services [5] - The company provides OGM solutions applicable in various research fields, including basic, translational, and clinical research [5] - Bionano also offers diagnostic testing services through its subsidiary, Lineagen, Inc., which utilizes OGM technology [5] Research Developments - The initial study utilizing OGM for chromoanagenesis was published in January 2025, focusing on acute myelogenous leukemia (AML) [3] - The book series includes studies expanding OGM applications to other cancers like multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) [3] - New methodologies, such as dam-assisted fluorescent tagging of chromatin accessibility, are being developed for detailed analysis of chromatin structures [3]

Core Insights - Bionano Laboratories announced a preliminary payment determination from CMS for a new CPT code for optical genome mapping (OGM) in detecting genetic disorders, priced at $1263.53, which is higher than existing microarray codes [1][2][3] Group 1: CPT Code and Pricing - The new Category I CPT code for OGM will facilitate reimbursement for laboratory developed tests (LDTs) based on OGM, providing a pricing advantage over traditional methods [2][3] - The new CPT code 81354 for constitutional genetic disease analysis is expected to be priced at $1263.53, which is $363.53 higher than code 81228 and $103.53 higher than code 81229 [1][2] Group 2: Clinical Applications and Impact - OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV are expected to be covered under the new CPT code, indicating their relevance in clinical settings [2][3] - The introduction of this CPT code is anticipated to enhance awareness and support for OGM in both oncology and clinical genetic testing communities globally [3] Group 3: Company Overview - Bionano Laboratories, a subsidiary of Bionano Genomics, specializes in CLIA-certified LDTs utilizing OGM technology to advance genetic diagnostics [4][5] - The company aims to transform genome analysis through innovative solutions and diagnostic services, including OGM and related software [5]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 921 ...